Simulations Plus

Simulations Plus provides biosimulation software and scientific services that support drug development from discovery through commercialization. For more than three decades, the company has worked with scientists and pharmaceutical teams to apply model-informed drug development, combining mechanistic modeling with AI-enabled workflows to help inform decisions across the drug lifecycle. Its tools support ADMET prediction, pharmacokinetics, pharmacometrics, quantitative systems pharmacology, and quantitative systems toxicology.

The software portfolio includes GastroPlus for absorption, biopharmaceutics, pharmacokinetic, and pharmacodynamic simulations; MonolixSuite for pharmacometrics analysis and modeling; ADMET Predictor for machine-learning-based assessment and drug design; DILIsym for investigating potential drug-induced liver injury; and Thales for building and analyzing QSP models. Pro-ficiency provides performance management and training through simulation, data tracking, and analytics.

Simulations Plus also offers consulting to help clients develop models, interpret results, and shape regulatory and commercial strategies. Additional services include learning programs, workshops, webinars, and training. The company’s stated focus is translating rigorous science into trusted tools that help teams make more confident development decisions.